Cardio- and cerebrovascular risk with conventional synthetic disease-modifying antirheumatic drugs (CSDMARDS) in rheumatic arthritis (RA): a real-world comparative assesment

Benzer Materyaller

• Is Farming a Risk Occupation for Cardio-cerebrovascular Diseases? A Scoping Review on Cardio-cerebrovascular Disease Risk in Farmers
  Yazar:: Hyeonjun Kim, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-11-01)
• VZV-specific T-cell levels in patients with rheumatic diseases are reduced and differentially influenced by antirheumatic drugs
  Yazar:: David Schub, ve diğerleri
  Baskı/Yayın Bilgisi: (2018-11-01)
• Inhibition of bone erosion, determined by high-resolution peripheral quantitative computed tomography (HR-pQCT), in rheumatoid arthritis patients receiving a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) plus denosumab vs csDMARD therapy alone: an open-label, randomized, parallel-group study
  Yazar:: Naoki Iwamoto, ve diğerleri
  Baskı/Yayın Bilgisi: (2022-12-01)
• Long-term efficacy of baricitinib in patients with rheumatoid arthritis who have had inadequate response to csDMARDs: results from ra-beyond up to 7 years of treatment
  Yazar:: Caporali, R, ve diğerleri
  Baskı/Yayın Bilgisi: (2022)
• Mg alloy cardio-/cerebrovascular scaffolds: Developments and prospects
  Yazar:: Shaokang Guan, ve diğerleri
  Baskı/Yayın Bilgisi: (2023-11-01)